Controlling the polycythemia effect associated with TRT

The goal of this study was to determine how to minimize the secondary polycythemia effect observed in patients on testosterone replacement therapy (TRT). Patient hemoglobin, estradiol (E2) and total testosterone (TT) levels were used in this study to determine when a patient became “stable” on treatment. Stability was defined in this study as the point at which a patient’s symptoms have resolved, secondary polycythemia has stopped, and testosterone cypionate (TC) dosage has remained consistent for at least three months. Currently, secondary polycythemia associated with TRT is commonly being controlled by frequent blood donations, or therapeutic phlebotomies. However, this study shows that it is possible to minimize fluctuations in TT and E2 levels, which then minimizes side effects including secondary polycythemia. In this study, we found that the patients stabilized at TT levels between 605–1051 ng/dL. The effects of stable TC dosing were tracked and discussed in terms of total cholesterol, Prostate Specific Antigen (PSA) and A1c levels as well. These were not necessarily the focus of the study, but significant trends were noted once data was collected to warrant their inclusion in the study.

Testosterone replacement therapy; Total testosterone; Testosterone cypionate; Estradiol; Stabilization

[1] Travison TG, Vesper HW, Orwoll E, Wu F, Kaufman JM, Wang Y, et al. Harmonized reference ranges for circulating testosterone levels in men of four cohort studies in the United States and Europe. The Journal of Clinical Endocrinology & Metabolism. 2017; 102: 1161–1173.

[2] Regenx Health. LabCorp vs. quest laboratories serum testosterone assays & reference ranges. 2020. Available at: https://www.regenxhealth.com/post/labcorp-vs-quest-laboratories-serum-testosterone-assays-reference-range (Accessed: 05 June 2023).

[3] Hormone Therapeutics. Here’s what you should know more about testosterone levels. 2016. Available at: http://www.hormonetherapeutics.com/about-testosterone-levels/ (Accessed: 05 June 2023).

[4] Pantalone K. Why are testosterone levels decreasing? 2022. Available at: https://health.clevelandclinic.org/declining-testosterone-levels/ (Accessed: 13 May 2023).

[5] Lokeshwar SD, Patel P, Fantus RJ, Halpern J, Chang C, Kargi AY, et al. Decline in serum testosterone levels among adolescent and young adult men in the USA. European Urology Focus. 2021; 7: 886–889.

[6] Snyder PJ, Matsumoto AM, Martin KA. Testosterone treatment of male hypogonadism. 2022. Available at: https://www.uptodate.com/contents/testosterone-treatment-of-male-hypogonadism?search=testosterone%20dosing&source=search_result&selectedTitle=2~148&usage_type=default&display_rank=1 (Accessed: 03 May 2023).

[7] Stevens R. Gold standard TRT. 2018. Available at: https://themenshealthclinic.co.uk/gold-standard-trt/ (Accessed: 07 May 2023).

[8] Bhasin S. Testosterone replacement in aging men: an evidence-based patient-centric perspective. Journal of Clinical Investigation. 2021; 131: e146607.

[9] Mayo Clinic. Testosterone therapy: Potential benefits and risks as you age. 2022. Available at: https://www.mayoclinic.org/healthy-lifestyle/sexual-health/in-depth/testosterone-therapy/art-20045728 (Accessed: 03 May 2023).

[10] Mohammadi-Shemirani P, Chong M, Pigeyre M, Morton RW, Gerstein HC, Paré G. Effects of lifelong testosterone exposure on health and disease using Mendelian randomization. eLife. 2020; 9: e58914.

[11] Basaria S, Harman SM, Travison TG, Hodis H, Tsitouras P, Budoff M, et al. Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels. JAMA. 2015; 314: 570–581.

[12] Terranella R. Testosterone replacement therapy dosing and dosage considerations. 2014. Available at: https://www.swintegrativemedicine.com/blog/testosterone-replacement-therapy-dosing-and-dosage-considerations (Accessed: 03 May 2023).

[13] Walther A, Breidenstein J, Miller R. Association of testosterone treatment with alleviation of depressive symptoms in men. JAMA Psychiatry. 2019; 76: 31–40.

[14] Halpern JA, Brannigan RE. Testosterone deficiency. JAMA. 2019; 322: 1116.

[15] Chasland LC, Yeap BB, Maiorana AJ, Chan YX, Maslen BA, Cooke BR, et al. Testosterone and exercise: effects on fitness, body composition, and strength in middle-to-older aged men with low-normal serum testosterone levels. American Journal of Physiology-Heart and Circulatory Physiology. 2021; 320: H1985–H1998.

[16] Barone B, Napolitano L, Abate M, Cirillo L, Reccia P, Passaro F, et al. The role of testosterone in the elderly: what do we know? International Journal of Molecular Sciences. 2022; 23: 3535.

[17] Lakshman KM, Kaplan B, Travison TG, Basaria S, Knapp PE, Singh AB, et al. The effects of injected testosterone dose and age on the conversion of testosterone to estradiol and dihydrotestosterone in young and older men. The Journal of Clinical Endocrinology & Metabolism. 2010; 95: 3955–3964.

[18] Plourde PV, Dyroff M, Dowsett M, Demers L, Yates R, Webster A. ARIMIDEX™: a new oral, once-a-day aromatase inhibitor. The Journal of Steroid Biochemistry and Molecular Biology. 1995; 53: 175–179.

[19] Aveta A, Cilio S, Contieri R, Spena G, Napolitano L, Manfredi C, et al. Urinary MicroRNAs as biomarkers of urological cancers: a systematic review. International Journal of Molecular Sciences. 2023; 24: 10846.

[20] Jepson JH, Lowenstein L. Inhibition of the stem cell action of erythropoietin by estradiol valerate and the protective effects of 17-á-hydroxyprogesterone caproate and testosterone propionate. Endocrinology. 1967; 80: 430–434.

[21] Lindemann R. Erythropoiesis inhibiting factor (EIF) the inhibitory effect of oestrogens on erythropoiesis and the content of oestrogens in the urinary EIF. Scandinavian Journal of Haematology. 1973; 11: 319–324.